| MeSH term | MeSH ID | Detail |
|---|---|---|
| Peroneal Neuropathies | D020427 | 1 associated lipids |
| Poxviridae Infections | D011213 | 1 associated lipids |
| Kaposi Varicelliform Eruption | D007617 | 1 associated lipids |
| Lacerations | D022125 | 1 associated lipids |
| Megacolon, Toxic | D008532 | 1 associated lipids |
| Tinea Capitis | D014006 | 1 associated lipids |
| Polyomavirus Infections | D027601 | 1 associated lipids |
| Lymphohistiocytosis, Hemophagocytic | D051359 | 1 associated lipids |
| Rheumatoid Nodule | D012218 | 1 associated lipids |
| Hernia, Ventral | D006555 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Saliba F et al. | Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. | 2017 | Am. J. Transplant. | pmid:28133906 |
| de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
| Elens L and Haufroid V | Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22? | 2017 | Pharmacogenomics | pmid:29095105 |
| Ma X et al. | Inhibition effect of tacrolimus and platelet-derived growth factor-BB on restenosis after vascular intimal injury. | 2017 | Biomed. Pharmacother. | pmid:28633129 |
| Gu K et al. | Atypical pneumonia due to human bocavirus in an immunocompromised patient. | 2017 | CMAJ | pmid:28507089 |
| Sanghavi K et al. | Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. | 2017 | Pharmacogenomics J. | pmid:26667830 |
| Heemann U and Viklicky O | Is trough level variability the new tool for identifying patients at risk for rejection after transplantation? | 2017 | Nephrol. Dial. Transplant. | pmid:28186537 |
| Undre N and Dickinson J | Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. | 2017 | BMJ Open | pmid:28377389 |
| Størset E et al. | Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. | 2017 | Br J Clin Pharmacol | pmid:28374426 |
| Ericzon BG et al. | Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy. | 2017 | Clin Transplant | pmid:28295581 |
| Smolders EJ et al. | Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation? | 2017 | Int. J. Antimicrob. Agents | pmid:28185946 |
| Sakurai K et al. | Efficacy of combination therapy with tacrolimus and mizoribine for cyclophosphamide-resistant ANCA-associated glomerulonephritis. | 2017 | Int J Rheum Dis | pmid:28205382 |
| Nishiya Y et al. | A new efficient method of generating photoaffinity beads for drug target identification. | 2017 | Bioorg. Med. Chem. Lett. | pmid:28108248 |
| Wungwattana M and Savic M | Tacrolimus interaction with nafcillin resulting in significant decreases in tacrolimus concentrations: A case report. | 2017 | Transpl Infect Dis | pmid:28067989 |
| MartÃn-Fernández M et al. | Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. | 2017 | Transplant. Proc. | pmid:29149986 |
| Nakamura K et al. | AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. | 2017 | Eur. J. Pharmacol. | pmid:27993641 |
| Gelens MACJ et al. | No evidence for progressive deterioration in stimulated insulin secretion in renal transplant recipients after 12years tacrolimus exposure. | 2017 | J. Diabetes Complicat. | pmid:28720321 |
| Chen P et al. | Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. | 2017 | J Clin Pharm Ther | pmid:27885697 |
| Zhang W et al. | Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. | 2017 | Transplantation | pmid:28885495 |
| Burbulla LF et al. | Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. | 2017 | Science | pmid:28882997 |